Audrey Cacaly MSc
Principal
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.
F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat potentially life-threatening invasive fungal infections.
F2G has discovered and developed a completely new class of antifungal agents called the orotomides which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range of rare and resistant fungal mold infections. For more information, please visit: www.f2g.com
Industry
Biotech
Status
Current
Our partnership with Forbion has been instrumental to secure several oversubscribed, private financing rounds to support registrational studies for olorofim, the first novel mechanism antifungal drug in decades. Through Forbion’s network and operational expertise, we were able to add critical resources to our team to accelerate recruitment into our global, Phase 3 trial, which is now on track to achieve top-line results in 2026. We are excited to continue our partnership with Forbion and make olorofim available to patients with fungal infections worldwide.Francesco Lavino
CEO of F2G
200
patients enrolled in Phase 2b study
Forbion team
Nanna Lüneborg PhD, MBA
General Partner